Results 41 to 50 of about 581 (108)

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Oncofetal Biology: From Fundamental Mechanisms to Emerging Therapeutic Opportunities

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Oncofetal biology provides a transformative framework for understanding cancer initiation, progression, and therapeutic intervention. This review synthesizes the core molecular mechanisms connecting embryonic development and tumorigenesis from a multidisciplinary standpoint and outlines future research trajectories and clinical applications, and we aim
Yang Liu, Kaifeng Niu, Qingran Kong, Shaorong Gao   +3 more
wiley   +1 more source

Restoring Iron Homeostasis via Smoothened Inhibition: A Novel Strategy Against Hearing Loss

Advanced Science, Volume 13, Issue 29, 22 May 2026.
 . ABSTRACT Sensorineural hearing loss (SNHL) induced by noise or aminoglycoside antibiotics is a significant public health concern without any FDA‐approved pharmaceutical therapies. Dysregulation of iron homeostasis and its subsequently induced ferroptosis has increasingly been identified as a key mechanism underlying cochlear hair cell (HC) damage ...
Huanyu Mao, Xiang Li, Yaqi Liao, Liman Liu, Xian Gao, Hailiang Lin, Wenli Ni, Huawei Li, Yan Chen, Wenyan Li   +9 more
wiley   +1 more source

Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion [PDF]

, 2020
Sonidegib and vismodegib are hedgehog pathway inhibitors (HhIs) approved for the treatment of advanced basal cell carcinoma (BCC). Until recently, vismodegib was the only targeted treatment available for patients with locally advanced BCC (laBCC) in ...
Dummer, R, J.T. Lear, Basset- Seguin, N, Schadendorf, D, R. Krattinger, R. Dummer, Grob, J, Grob, R J J, Krattinger, R, R. Gutzmer, D. Schadendorf, C. Garbe, J.J. Grob, P.A. Ascierto, Dréno, B, J. Malvehy, Lear, J T, Ascierto, P, Malvehy, J, Gutzmer, R, Lear, J, Basset-Seguin, N, B. Dréno, N. Basset‐Seguin, Ascierto, P A, Hauschild, A, A. Hauschild, Garbe, C, Malvehy J, Schadendorf D, Dummer R, Grob RJJ, Garbe C, Lear JT, Ascierto PA, Dréno B, Hauschild A, Gutzmer R, Krattinger R, Basset-Seguin N   +39 more
core   +1 more source

Sonidegib efficacy and safety in ultra‐nonagenarian patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Camilla Brunello, Andrea Corio, Marco Zanette, Raffaele Dante Caposiena Caro, Iris Zalaudek, Nicola di Meo   +5 more
wiley   +1 more source

Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice

BMC Cancer, 2017
Background 177Lu-octreotate can be used to treat somatostatin receptor expressing neuroendocrine tumors. It is highly effective in animal models, but clinical studies have so far only demonstrated low cure rates.
Johan Spetz, Britta Langen, Nils Rudqvist, Toshima Z. Parris, Khalil Helou, Ola Nilsson, Eva Forssell-Aronsson   +6 more
doaj   +1 more source

Integrated Molecular Profiling Improves Subtype Classification and Reveals Inherited Susceptibility in Medulloblastoma: Insights From a Real‐World Cohort

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Medulloblastoma (MB) is a heterogeneous pediatric brain tumor characterized by distinct molecular subtypes. Although genomics and transcriptomics have improved subtype classification and informed targeted therapies, the clinical utility of integrated molecular profiling in real‐world settings remains incompletely defined. Methods We
Jiwei Song, Tiantian Han, Siqi Chen, Dongsheng Chen, Ziying Liu   +4 more
wiley   +1 more source

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

26 | Tumor size may predict early response to sonidegib in locally-advanced basal cell carcinoma: clinical and histopathological correlates from a monocentric case series

Dermatology Reports
Background: Sonic Hedgehog (SHH) inhibitors, including sonidegib, have emerged as effective therapies for locally advanced basal cell carcinoma (LA-BCC). However, variability in clinical response has been observed.
Italian Melanoma Intergroup
doaj   +1 more source

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia, Giulia Hyeraci, Anna Girardi, Rosa Gini, Gianluca Trifirò, Ylenia Ingrasciotta, Andrea Spini, Valentina Ientile, Elisabetta Poluzzi, Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, Casula Manuela, Elena Tragni, Olivia Leoni, Arianna Mazzone, Michele Ercolanoni, Martina Zanforlini, Ursula Kirchmayer, Belleudi Valeria, Marco Finocchietti, Francesco Barone‐Adesi, Giuseppe Roberto   +21 more
wiley   +1 more source